Tumor necrosis factor receptor
superfamily, member 17 (TNFRSF17), also known as B cell maturation
antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor
superfamily. This receptor is preferentially expressed in mature B
lymphocytes, and may be important for B cell development and autoimmune
response. This receptor has been shown to specifically bind to the tumor
necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to
lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also
binds to various TRAF family members, and thus may transduce signals for
cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for
TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and
IKK-dependent pathway. The identification of TNFRSF17 as a
NF-kappaB-activating receptor for TALL-1 suggests molecular targets for
drug development against certain immunodeficient or autoimmune diseases.
TNFRSF17/BCMA is a target of donor B-cell immunity in patients with
myeloma who respond to DLI. Antibody responses to cell-surface BCMA may
contribute directly to tumor rejection in vivo.
全称
tumor necrosis factor receptor superfamily member 17
参考文献
Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94.
O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8.
Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.